CN112646030A

CN112646030A - Application of pharmaceutical composition containing mesenchymal stem cell exosomes in treating diseases

Info

Publication number: CN112646030A
Application number: CN202110027715.6A
Authority: CN
Inventors: 张海涛; 王青
Original assignee: Beijing Xinsong Biotechnology Co ltd
Current assignee: Inner Mongolia chuangrun Biotechnology Co., Ltd
Priority date: 2021-01-11
Filing date: 2021-01-11
Publication date: 2021-04-13
Anticipated expiration: 2041-01-11
Also published as: CN112646030B

Abstract

The invention belongs to the technical field of biological pharmacy, and particularly relates to application of a pharmaceutical composition containing a mesenchymal stem cell exosome in treating diseases.

Description

Application of pharmaceutical composition containing mesenchymal stem cell exosomes in treating diseases

Technical Field

The invention belongs to the field of biological pharmacy, and particularly relates to application of a pharmaceutical composition containing mesenchymal stem cell exosomes in treating diseases.

Background

Fibrosis is a chronic progressive disease characterized by fibrosis of tissues, and human organs are composed of parenchyma and interstitium, wherein parenchyma refers to main structural and functional cells of an organ and plays a main physiological function of the organ, and interstitium is composed of interstitial cells and extracellular matrix and mainly plays a role in mechanical support and connection, when organ tissues are damaged or subjected to other abnormal physiological signals, massive proliferation of interstitial fibrous connective tissues can be caused, original normal structures of the organ are damaged, organ fibrosis and function are reduced, and various diseases such as liver fibrosis, kidney fibrosis, lung fibrosis, cardiac fibrosis, skin fibrosis and the like are induced. Pulmonary Fibrosis (PF), also known as Diffuse Parenchymal Lung Disease (DPLD), is a common one of many fibrotic diseases, and is a chronic inflammatory disease characterized by infiltration of interstitial lung inflammatory cells, fibroblast proliferation and collagen deposition, and the initial stage of the disease is referred to as alveolitis, in which a large number of inflammatory cells infiltrate into the lung, activate, release various cytokines, form a cascade effect, activate various cells, induce activation, proliferation and secretion of extracellular matrix of lung fibroblasts, and finally form pulmonary fibrosis.

The pathogenesis of pulmonary fibrosis is not clear, and may be related to multiple factors such as autoimmune deficiency, environmental pollution, bad living habits, external injury and the like. Currently, clinical treatment methods include antioxidants, anti-fibrosis agents, cytokine inhibitors, and the like, wherein pirfenidone and nintedanib have been approved for pulmonary fibrosis due to their ability to significantly slow down the rate of decrease in lung capacity, but the two drugs have limited therapeutic effects and may cause serious gastrointestinal tolerance problems, and have been found to cause nephrotoxicity in use, and also have been treated by oxygen therapy, mechanical ventilation, lung repair or lung transplantation, and researchers in China have developed various treatment methods of traditional Chinese medicines, such as yang-tonifying and lung-clearing decoction, yin-nourishing and lung-clearing decoction, ophiopogon decoction, epimedium extract, glycyrrhizic acid, astragalus polysaccharides, and the like. However, the above-mentioned therapeutic methods or drugs still have difficulty in effectively treating or alleviating pulmonary fibrosis, and studies have shown that median survival of patients with idiopathic pulmonary fibrosis is 2-4 years after diagnosis, 5-year survival rate is only 30% -50%, and prognosis is poor. Since pulmonary fibrosis is difficult to be effectively treated clinically and the incidence rate of pulmonary fibrosis is on the trend of increasing year by year, the research on pulmonary fibrosis drugs becomes a research hotspot in the current medical field.

With the development of modern molecular biology and immunology, immunotherapy provides a new solution for the treatment of pulmonary fibrosis. It is widely believed that inflammatory responses of the lung play an important role in the development of pulmonary fibrosis, and inflammatory factors such as Interleukin (IL), Tumor Necrosis Factor (TNF), prostaglandin E2(prostaglandin E2, PGE2) are receiving extensive attention from researchers, and among them, IL-17 has been studied more in recent years. IL-17 as a secretory protein, composed of 150-180 amino acids, IL-17 must bind with IL-17R receptor on its cell membrane to play a role, IL-17R is a single transmembrane protein, and is expressed in epithelial cells, stellate cells, fibroblasts and hematopoietic cells, and IL-17 effector cells mainly include epidermal cells, endothelial cells, fibroblasts, etc. Based on the research that IL-17 can influence the occurrence and development processes of pulmonary fibrosis by activating or blocking MAPK signal path, GSK3 beta signal path and NF-kB signal path, researchers develop a plurality of antibodies targeting IL-17 or IL-17R for treating pulmonary fibrosis, such as CN201180048098, CN201080019710, WO2012093254, WO2009015063 and the like which respectively disclose antibodies targeting IL-17 and the application thereof in treating pulmonary fibrosis. However, most of the existing targeted iL-17 antibodies are common monoclonal antibodies, the production and preparation cost is high, and the treatment effect is limited.

Mesenchymal Stem Cells (MSCs) are derived from mesoderm-derived non-hematopoietic cells, have low immunogenicity, multipotential differentiation capacity and tissue repair capacity, and are widely used for treating various diseases, and MSCs can be isolated from tissues such as bone marrow, adipose tissue, umbilical cord, etc., wherein human umbilical cord mesenchymal stem cells are more easily obtained, have proliferation and immunosuppressive effects, and have no ethical problems in clinical applications. After the inflammatory factors, the mesenchymal stem cells are also used for treating pulmonary fibrosis, but the mesenchymal stem cells are directly used for treating pulmonary fibrosis, on one hand, a large amount of primary cells need to be cultured, the process is complicated, the production and management cost is high, on the other hand, because the components of a culture medium used in the cell culture process are unclear, and the injection of exogenous xenobiotic stem cells causes graft-versus-host reaction, so the safety and the stability of the mesenchymal stem cells are questioned to a certain extent, and the clinical application and popularization are not facilitated, so researchers try to treat pulmonary fibrosis by using mesenchymal stem cell exosomes and obtain a certain positive effect, such as Yangjing and the like (umbilical cord mesenchymal stem cell-derived exosomes relieve pulmonary fibrosis by inhibiting epithelial-mesenchymal transformation, J South Med Univ, 2020, 40 (7): 988-, the degree of pulmonary fibrosis of mice is relieved by inhibiting epithelial-mesenchymal transformation activated by a TGF-beta 1/Smad2/3 signal channel, Zhanguo (curative effect and mechanism research of the bone marrow mesenchymal stem cell source exosome for inhibiting silicon dioxide induced pulmonary fibrosis, Jinan university, Master academic paper, 2019) adopts bone marrow mesenchymal stem cells (BMSCs) exosome stem pre-silicon dioxide induced pulmonary fibrosis, the lung coefficient of rats can be improved, and the expression level of the fibrosis promoting factor TGF-beta 1 is reduced. However, the mesenchymal stem cells have multidirectional differentiation, are not high in treatment targeting property and are easy to cause side reactions, so that the satisfactory curative effect is still difficult to obtain when the mesenchymal stem cells or exosomes are used for treating the pulmonary fibrosis, and the improvement of the pulmonary fibrosis degree is limited.

Aiming at the defects in the prior art, the invention provides a novel treatment means for pulmonary fibrosis, on one hand, a single-domain antibody targeting IL-17 is screened and obtained, and the antibody has a brand-new structure and can efficiently and specifically bind a target antigen; on the other hand, the preparation process of the umbilical cord source mesenchymal stem cell exosome is optimized, the exosome is extracted after the mesenchymal stem cell is co-cultured with the alveolar epithelial cell, and then the exosome and the single-domain antibody are jointly used for treating pulmonary fibrosis diseases, so that a synergistic effect is expected to be obtained, and a new means and a new method are provided for treating pulmonary fibrosis.

Disclosure of Invention

The invention mainly aims to provide a targeting IL-17 single-domain antibody and combined application of the targeting IL-17 single-domain antibody and a mesenchymal stem cell exosome, which can generate a synergistic effect, effectively inhibit the occurrence and development process of pulmonary fibrosis, promote repair of alveolar tissues, contribute to recovery of lung physiological functions and improve treatment effects.

The detailed technical scheme of the invention is as follows:

provided is a single domain antibody targeting IL-17, characterized in that the amino acid sequence of the complementarity determining region (CDR region) of the single domain antibody is: CDR1 shown in SEQ ID NO. 1, CDR2 shown in SEQ ID NO. 2 and CDR3 shown in SEQ ID NO. 3.

Furthermore, the amino acid sequence of the single domain antibody is shown as SEQ ID NO. 4.

Compared with the common monoclonal antibody with complete light chain and heavy chain structures, the single-domain antibody, also called nano antibody, only has the heavy chain structure, so that the molecular structure of the antibody is simpler, the later-stage production preparation and separation and purification are easy, and the single-domain antibody still has higher affinity and targeting property with a target antigen, thereby being more suitable for clinical application and large-scale production.

Provided is a pharmaceutical composition characterized by comprising the single domain antibody and the mesenchymal stem cell exosomes as described above.

Further, the mass ratio of the single-domain antibody to the mesenchymal stem cell exosome is 1:2-2: 1.

Further, the mesenchymal stem cells are derived from fat, bone marrow, umbilical cord or placenta.

Further, the mesenchymal stem cells are derived from umbilical cord.

Further, the preparation method of the mesenchymal stem cell exosome comprises the following steps: separating mesenchymal stem cells from umbilical cord tissues, carrying out subculture, culturing for 3-5 generations, replacing a serum-free culture medium for culturing for 24h when the fusion degree reaches more than 80%, collecting supernate, centrifuging, filtering and collecting.

Further, the mesenchymal stem cell exosome is an exosome obtained after the mesenchymal stem cell and the alveolar epithelial cell are co-cultured.

Further, the preparation method of the mesenchymal stem cell exosome comprises the following steps: separating mesenchymal stem cells from umbilical cord tissues, carrying out subculture, and culturing for 3-5 generations; inoculating the mesenchymal stem cells into a lower chamber of a Transwell culture chamber, and inoculating alveolar epithelial cells into an upper chamber of the Transwell culture chamber for co-culture; after co-culturing for a period of time, replacing serum-free culture medium to culture for 24h, collecting supernatant, centrifuging, filtering and collecting.

Further, the mesenchymal stem cells and the alveolar epithelial cells are cultured for 12-48 h.

Further, the mesenchymal stem cells are co-cultured with alveolar epithelial cells for 24 h.

Provides the application of the pharmaceutical composition in preparing medicaments for treating diseases related to tissue fibrosis.

Further, the disease includes pulmonary fibrosis, hepatic fibrosis, renal fibrosis or skin fibrosis.

Further, the disease is pulmonary fibrosis.

The beneficial effects of the invention include:

although the mesenchymal stem cell exosome has been reported to be used for treating pulmonary fibrosis, the treatment effect still needs to be enhanced, and the mesenchymal stem cell has multidirectional differentiation, so the treatment specificity is low, in order to improve the specificity, on one hand, the exosome of the mesenchymal stem cell and the single-domain antibody of the target IL-17 are used in a combined way, on the other hand, the exosome is collected after being co-cultured with the alveolar epithelial cell for a period of time in the culture process of the mesenchymal stem cell, a certain induced differentiation effect is achieved, and the treatment effect of the pulmonary fibrosis is improved on the whole.

The beneficial effects of the invention include:

the invention provides a single-domain antibody targeting IL-17, which can be combined with a target antigen with high specificity and treat pulmonary fibrosis, has a simpler biological structure and is easy to produce and prepare; the human umbilical cord mesenchymal stem cells are selected, have wide sources, are easy to culture and have no ethical problems; the stem cell exosomes are used for treating pulmonary fibrosis, so that the transplantation anti-host effect is avoided; the exosome is collected after the mesenchymal stem cells and the lung epithelial cells are co-cultured, initial induction is carried out, targeting is improved, and the mesenchymal stem cell exosome and the targeting IL-17 single-domain antibody are matched for use, so that a synergistic effect can be generated, and the pulmonary fibrosis treatment effect is further improved.

Drawings

FIG. 1 is a schematic representation of a model of cell co-culture;

FIG. 2 is a graph of pulmonary coefficients for different treatment groups;

FIG. 3 is a section view of pathological lung tissue of rats in different treatment groups;

FIG. 4 is a graph showing the effect of IL-6 expression in serum of rats of different treatment groups;

FIG. 5 is a graph showing the effect of TGF- β expression in serum of rats of different treatment groups;

FIG. 6 is a graph showing the effect of TNF- α expression in serum of rats of different treatment groups.

Detailed Description

The following non-limiting examples are presented to enable those of ordinary skill in the art to more fully understand the present invention and are not intended to limit the invention in any way. All the technologies implemented based on the above-mentioned contents of the present invention should fall within the scope of the claims of the present application.

The experimental methods described in the following examples are all conventional methods unless otherwise specified; the kit biomaterials, if not specifically indicated, are commercially available.

EXAMPLE 1 Single Domain antibody preparation targeting IL-17

The method for screening the IL-17 targeted single domain antibody by utilizing the human IL-17 protein to immunize the alpaca and through a phage display library comprises the following steps:

firstly, alpaca antigen immunization.

Fully mixing 100 mu g of human IL-17 protein and 100 mu L of Freund's complete adjuvant to prepare an emulsified mixture, selecting healthy adult monomodal camel, immunizing the alpaca by adopting the emulsified mixture in a back subcutaneous multipoint injection mode, adopting the Freund's complete adjuvant for the former two times of immunization, and performing enhanced immunization on the emulsified mixture formed by mixing the subsequent immunization with the Freund's incomplete adjuvant and the human IL-17 protein for 8-10 times in total, wherein the immunization interval time is 2 weeks. After 1 week of each immunization, 100mL of peripheral blood was collected and examined by ELISAMeasuring antiserum titer, coating detection plate with human IL-17 protein, adding antiserum diluted in gradient into each well, incubating at 37 deg.C for 1.5h, washing for 3-5 times, adding 10 per well⁴Diluting horseradish peroxidase-labeled secondary antibody, incubating at 37 deg.C for 1H, washing for 3-5 times, adding 100 μ L TMB substrate, incubating at 37 deg.C for 15min, and 50 μ L0.2M H₂SO₄The reaction was stopped, and the absorbance at OD 450nm was measured. When the antiserum titer reaches 10⁶In the above, an antibody phage display library was constructed.

And (II) constructing a phage display library.

Collecting 100mL of immunized alpaca Peripheral blood, separating by using lymphocyte separation liquid to obtain Peripheral Blood Mononuclear Cells (PBMC), extracting PBMC total RNA, carrying out reverse transcription by using an RT-PCR kit through oligo (dT) to obtain cDNA, amplifying by using a universal primer, carrying out enzyme digestion and purification on a VHH gene segment of the alpaca, cloning to phagemid plasmid, transforming TG1 bacteria, culturing and enriching, connecting nucleic acid containing the VHH gene segment to a phage vector, and then carrying out electric shock transformation to construct a phage library. And randomly selecting 60 clones for sequencing identification, wherein the result shows that the positive rate of the constructed phage library is 96.7%, the sequence diversity is 97.1%, and the requirement of subsequent experiments is met.

(III) screening of target antibody

In the experiment, a single-domain antibody targeting IL-17 is obtained by three rounds of screening, and the specific steps are as follows:

first screening: coating natural human IL-17 protein on ELISA plate, 5 ug/well, 4 ℃ overnight; dissolving BSA with PBST to a concentration of 3%, 300. mu.L/well, blocking at 37 ℃ for 2h, and washing the plate for 3 times; adding 100 mu L of phage library solution into each hole, incubating for 2h at 37 ℃, and washing the plate for 3-5 times; adding glycine buffer solution, shaking gently for 10min at room temperature, sucking out the eluent, and adding Tris-HCl buffer solution for neutralization reaction. mu.L of the eluate was added to 5mL of TG1 strain in the logarithmic growth phase, incubated at 37 ℃ for 30min, and then added to a medium containing antibiotics, and cultured overnight at 37 ℃. Centrifuging the culture solution at 4 deg.C and 4000rpm for 15min, collecting supernatant, adding 5mL PEG/NaCl, ice-cooling for 30min, centrifuging at 4 deg.C and 8000rpm for 15-20min, discarding supernatant, re-suspending with 1mL PBS at 4 deg.C and 12000rpm, and centrifuging for 10min to obtain precipitate as phage antibody particles.

And (3) second screening: coating natural human IL-17 on an ELISA plate, wherein each hole is 1 mu g, and washing the plate for 3-5 times; washing the plate 3-5 times with 3% skimmed milk powder; adding 100 mu L of phage library solution into each hole, incubating for 2h at 37 ℃, and washing the plate for 5-8 times; the rest of the operations are the same as the first round of screening.

And (3) third screening: coating natural human IL-17 on an ELISA plate, wherein each hole is 0.1 mu g, and washing the plate for 3-5 times; blocking with 3% BSA, and washing the plate 3-5 times; adding 100 mu L of phage library solution into each hole, incubating for 2h at 37 ℃, and washing the plate for 5-8 times; the rest of the operations are the same as the first round of screening.

After screening, TG1 bacteria were infected with phage, plated on petri dishes, 80 single clones were randomly picked from the plates after cultivation, positive clones were screened by ELISA using soluble human IL-17 as antigen, and sequencing was performed. According to the sequencing results, 10 sequences were selected for subsequent experiments.

(IV) expression and analysis of target antibodies

Extracting positive clone plasmid and transforming to colibacillus competent cell, inducing single domain antibody protein expression by 100mM IPTG, and purifying target antibody protein by adopting a mode of mutually matching membrane separation and resin separation. The Fortebio biomolecule interaction platform is used for detecting the affinity, the result shows that the affinity of 6 antibodies and the target antigen in 10 alternative antibodies is between 2.71E-07 and 8.14E-09, and the single-domain antibody with the highest affinity is selected for subsequent experiments.

(V) Single Domain antibody sequence analysis

The amino acid sequence structure of the IL-17 single domain antibody is determined, as shown in SEQ ID NO. 4, the amino acid sequence is placed in a structure database to search a homologous structure and compare and analyze the antibody sequence structure, and the complementary determining regions (CDR regions) are determined, wherein the amino acid sequences of CDR1, CDR2 and CDR3 are sequentially shown in SEQ ID NO. 1-3.

Example 2 isolation, culture and exosome acquisition of human umbilical cord MSCs

2.1 isolation and culture of human umbilical cord MSCs

(1) Collecting fresh umbilical cord in sterile environment of operating room, taking the whole umbilical cord, and rapidly placing the whole umbilical cord in sterile PBS solution containing 0.5% penicillin and 0.5% streptomycin sulfate;

(2) in a biological safety cabinet, taking out the umbilical cord tissue, placing the umbilical cord tissue in sterile PBS solution, repeatedly washing the umbilical cord, and removing residual blood and other impurities; (3) cutting the umbilical cord into a plurality of sections, longitudinally splitting the umbilical cord, and removing two umbilical arteries and one umbilical vein;

(4) the umbilical cord is cut to about 1mm by using a sterile surgical scissors³Filtering the obtained tissue block by a 200-mesh filter screen to remove smaller tissue debris and cell debris;

(5) uniformly spreading the tissue blocks on a culture dish, adding DMEM/F12 culture medium containing 10% Fetal Bovine Serum (FBS), placing in a constant temperature incubator at 37 deg.C and 5% CO₂Culturing;

(6) after culturing for 24 hours, observing the adherence condition of the cells by a microscope, if the adherence is good, slightly sucking the culture medium by using a suction pipe or a pipette, and slightly rinsing the culture medium once by using a serum-free culture medium to remove tissue residues and cell fragments; if the adherent state is not good, continuing culturing until the adherent state is not good, and then performing the treatment;

(7) adding 10mL of 10% FBS-containing medium, and standing in a constant temperature incubator at 37 deg.C and 5% CO for 2-5 days₂；

(8) When the adherent cells in the culture dish are more than 60 percent fully spread, digesting for 3 minutes by using 1mL of 0.25 percent recombinant trypsin, then adding 10mL of culture medium to terminate the digestion, slightly blowing and beating into single cell suspension by using a pipette, centrifuging for 5 minutes at 1000rpm, discarding supernatant, and resuspending by using 10mL of fresh culture medium to obtain primary umbilical cord mesenchymal stem cells (marked as P0 generation);

(9) subculturing the umbilical cord mesenchymal stem cells of the P0 generation obtained in the step (8) for 3-5 generations (marked as P3-5 generations).

2.2 acquisition of human umbilical cord MSCs exosomes

(1) After the fusion degree of the cultured mesenchymal stem cells P3-P5 generation reaches more than 80%, sucking out the culture medium, replacing the serum-free culture medium for culturing for 24h, and collecting the supernatant;

(2) centrifuging the obtained supernatant at 2000rpm for 30min to remove cell debris, collecting supernatant, filtering with 0.22 μm sterile filter membrane to obtain filtrate, centrifuging at 10000rpm for 60min, discarding supernatant, and resuspending the obtained precipitate, i.e. human umbilical cord MSCs exosomes, with appropriate amount of PBS;

(3) the obtained exosome is subjected to NTA, transmission electron microscope observation and flow cytometry detection, and the result shows that the separated exosome can positively express CD9, CD63 and CD44 and negatively express CD34, has a vesicular structure, has an average diameter of about 100-120nm, and meets the experimental requirements.

Example 3 Co-culture of human umbilical cord MSCs with A549 cells and obtaining of exosomes

3.1 Co-culture of human umbilical cord MSCs and A549 cells

Human umbilical cord MSCs and A549 cells are co-cultured by adopting a Transwell culture chamber, and a semipermeable membrane is arranged at the bottom of the culture chamber, so that nutrient substances can be exchanged, but the cells cannot pass through the culture chamber.

(1) Collecting alveolar epithelial cells A549 (stored in laboratory) stored in liquid nitrogen, rapidly recovering in warm water, adding RPMI1640 culture medium, mixing, centrifuging at 2000rpm for 5min, collecting cells, washing with fresh culture medium for 3-5 times, adding RPMI1640 containing 10% FBS, and culturing at 37 deg.C under 5% CO₂Culturing for 3-5 passages under conditions to substantially activate a549 cells;

(2) human umbilical cord MSCs were cultured and passaged to 3-5 passages as described in section 2.1;

(3) human umbilical cord MSCs were seeded into the lower chamber of a Transwell culture chamber 10 per well⁶Individual cells, A549 cells, were seeded into the upper chamber of a Transwell culture chamber 10 per well ⁶1, as shown in figure 1, the cell is a Transwell culture chamber, the bottom of the chamber is provided with a semipermeable membrane 2, the upper chamber is inoculated with A549 cells 3, and the bottom of the lower chamber is inoculated with human umbilical cord MSCs 4;

(4) adding complete DMEM/F12 medium to the CO-culture model obtained in (3) at 37 ℃ and 5% CO₂And culturing for 24 h.

3.2 obtaining exosomes after co-culturing human umbilical cord MSCs and A549 cells

CO-culturing human umbilical cord MSCs and A549 cells for 24h, discarding the original culture medium, gently washing with PBS for 3 times, adding serum-free culture medium, 37 deg.C, and 5% CO₂And after the exosome is continuously cultured for 24 hours, collecting the exosome, wherein the specific method is as in section 2.2, and carrying out NTA, transmission electron microscope observation and flow cytometry detection on the obtained exosome, wherein the result shows that the separated exosome can positively express CD9, CD63 and CD44 and negatively express CD34, has a vesicular structure, has the average diameter of about 100-120nm, and meets the experimental requirements.

Example 4 treatment and evaluation of rats with pulmonary fibrosis

4.1 preparation of pulmonary fibrosis rat model

The bleomycin is a conventional medicament for preparing a pulmonary fibrosis model, the induced pulmonary fibrosis model has similar physiological and pathological characteristics with human pulmonary fibrosis, and is widely used for research and treatment of the pulmonary fibrosis, and the method is mature and is simple and convenient to operate, so that the bleomycin is adopted to induce the pulmonary fibrosis of rats, and the specific steps are as follows:

(1) cleaning SD (Sprague-Dawley) rats are taken, 8-10 weeks old, the body weight is about 180-;

(2) after the SD rat is anesthetized by 10% chloral hydrate, the weight of the rat is measured and recorded, and the administration dosage of each rat is calculated according to the experimental dosage of 5mg/kg of bleomycin;

(3) fixing a rat on a laboratory table, disinfecting the throat part by adopting iodophor, cutting off the throat part by using an operating scissors, exposing the trachea, injecting the calculated dose of bleomycin into the trachea by using a medical disposable injector, vertically placing the rat, and rotating the rat left and right for 3-4 weeks to uniformly distribute the bleomycin solution in the lung;

(4) the operation wound is sutured, the wound is disinfected by iodophor, and the rat is normally raised after waking.

4.2 treatment of rats with pulmonary fibrosis

In order to verify the therapeutic effect of the IL-17 antibody, the human umbilical cord MSCs and the combination thereof on pulmonary fibrosis, the drug is respectively adopted to treat rats with pulmonary fibrosis induced by bleomycin, and various indexes are observed so as to comprehensively investigate and evaluate the therapeutic effect.

The rats with pulmonary fibrosis are randomly divided into 6 groups, 10 rats in each group are respectively a normal saline group (marked as A group), and the tail vein is injected with 0.2mL of normal saline; IL-17 antibody group (marked as group B), tail vein injection 100 u g/Kg IL-17 antibody; separately culturing an exosome group (marked as group C), and injecting 100 mu g/Kg of separately cultured human umbilical cord MSCs exosome into tail vein; co-culturing an exosome group (marked as a group D), and injecting 100 mu g/Kg co-cultured human umbilical cord MSCs exosome into tail vein; IL-17 antibody + separately cultured exosome group (designated as group E), tail vein injecting 100 ug/Kg IL-17 antibody and 100 ug/Kg separately cultured human umbilical cord MSCs exosome; IL-17 antibody + coculture exosome group (designated as group F), 100. mu.g/Kg IL-17 antibody and 100. mu.g/Kg coculture of human umbilical cord MSCs exosomes were injected into the tail vein. After 1 week of molding, the above dose was administered, and the test was performed 4 weeks after administration.

4.3 evaluation of Lung coefficients in rats

After 4 weeks of treatment, rats in each experimental group were fasted and kept without water for 12 hours, the rats were dislocated and sacrificed, their respective weights were measured, and then lungs were separated and weighed under aseptic conditions, and a lung coefficient, which is lung wet weight (mg)/weight (g), was calculated according to the following formula. As shown in fig. 2, in the saline group, the lung coefficients of rats were severely reduced, indicating that bleomycin caused severe damage to lung tissues, and the lung coefficients in the respective treatment groups were improved to different degrees, wherein the improvement degree of group C was lower, indicating that it was difficult to effectively alleviate or improve pulmonary fibrosis symptoms using only exosomes from human umbilical cord MSCs; the lung coefficient recovery degree of the group B and the group D is higher than that of the group C, which indicates that exosome obtained by co-culture of the IL-17 antibody, human umbilical cord MSCs and A549 cells can effectively improve the condition of pulmonary fibrosis, on one hand, the targeted IL-17 single-domain antibody provided by the invention can be combined with a target antigen with high specificity, so as to induce and activate a related signal path in vivo and play a role in anti-fibrosis; on the other hand, because the mesenchymal stem cells have multidirectional differentiation and multipotential repair capacity, only the simple exosomes of the human umbilical cord MSCs are used, the targeting is not strong, and the strong repair effect on specific tissues and damages thereof is difficult to generate, and after the mesenchymal stem cells are co-cultured with the alveolar epithelial cells, the mesenchymal stem cells can play a certain role in qualitative induction or activation, secrete more targeted metabolites and further play a strong role in treatment. Similar effects also appear in the combined treatment group of the antibody and the exosome, and the treatment effect of using the IL-17 antibody and culturing the exosome of the human umbilical cord MSCs alone is similar to that of using the IL-17 antibody alone, although the lung coefficient is increased to a certain extent, the lung coefficient is not obvious, and the statistical difference is not shown; the IL-17 antibody and the exosomes of co-cultured human umbilical cord MSCs exhibited a synergistic effect with the lung coefficient being highest in each treatment group and significantly greater than each treatment group alone.

4.4 rat Lung tissue section detection

After 4 weeks of treatment, rats were sacrificed (the sacrifice method is the same as that in section 4.3), lung tissues of rats in each treatment group were taken and fixed in 10% formalin solution for 3 days, then the lung tissues were taken out and washed with clear water, the lung tissues were dehydrated, paraffin was used to embed the lung tissues, then the lung tissues were sliced by a microtome, prepared into pathological sections after HE staining, and changes of the lung tissues were observed under a microscope.

As shown in fig. 3, in the normal saline group (group a), the alveolar structure is disturbed, fusion occurs between different alveoli, and the alveolar space is heavily infiltrated by inflammatory cells and is heavily proliferated by fibroblasts, and the extracellular matrix is deposited; culturing exosome group alone (group C) and co-culturing exosome group (group D) showed only slight improvement, especially large numbers of inflammatory cells and fibroblasts still visible in group C lung tissue; the IL-17 antibody group (group B) was improved significantly, inflammatory cells decreased, and alveolar structures began to recover; the IL-17 antibody + single culture exosome group (group E) and the IL-17 antibody + co-culture exosome group (group F) are improved more obviously, an intact alveolar structure is generated, a large number of inflammatory cells are reduced, and the treatment effect of the group F is more obvious from pathological section.

4.5 rat serum inflammatory factor assay

After 4 weeks of treatment, the tail vein of the rat was bled, and then centrifuged at 3000rpm for 15min to collect serum, and the concentrations of IL-6, TGF-beta and TNF-alpha were measured using an enzyme-linked immunosorbent assay (ELISA) kit, with the specific measurement steps being performed according to the kit instructions, and the results are shown in FIGS. 4-6.

IL-6, TGF-beta and TNF-alpha are considered to be serious factors closely related to the development of pulmonary fibrosis, and can influence the progress of tissue fibrosis through NF-kappa B, JAK-STAT, BMP and other signaling pathways. As shown in FIG. 4, in terms of IL-6 expression level, the IL-17 antibody provided by the present invention can effectively reduce the expression level of IL-6 in a pulmonary fibrosis model, while IL-6 secretion is difficult to effectively improve by using separately cultured MSCs exosomes, and co-cultured MSCs exosomes can obviously reduce the expression level of IL-6, but the improvement range is lower than that of IL-17 antibody, and surprisingly, the IL-17 antibody and exosomes can be used for synergistic treatment to greatly reduce the expression level of IL-6, and both group E and group F in FIG. 4 can obviously reduce the expression level of IL-6, wherein the effect of group F is more obvious and is obviously lower than that of group IL-17 antibody (i.e. group A). As shown in FIG. 5, the improvement effect of the antibody-treated group (group A) and the exosome-treated group (group B and group C) was not significant in terms of TGF- β expression level, but was only slightly reduced in the normal saline control group, but the TGF- β expression level was significantly reduced by the IL-17 antibody and exosome synergistic treatment, and the effect was more significant by the IL-17 antibody and co-culture of exosomes. As shown in fig. 6, in terms of TNF- α expression level, a similar trend to IL-6 is exhibited, the IL-17 antibody can significantly down-regulate TNF- α expression, but the improvement of mesenchymal stem cell exosomes is not large, and although IL-17 antibody and exosome synergistic treatment can also significantly reduce TNF- α expression level, there seems to be no advantage in using IL-17 antibody alone, which may be related to complex inflammatory factor signal expression in the body, but in combination with lung tissue coefficients and pathological section experimental results, a scheme of IL-17 antibody and exosome synergistic treatment, especially a scheme of IL-17 antibody and MSCs and alveolar epithelial cell co-culture exosome synergistic treatment, is still worthy of recommendation, and provides a new feasible approach for clinical treatment of pulmonary fibrosis.

Sequence listing

<110> Beijing Song Biotechnology Ltd

<120> use of a pharmaceutical composition comprising mesenchymal stem cell exosomes for treating diseases

<160> 4

<170> SIPOSequenceListing 1.0

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 1

Tyr Val Pro Pro Ser Tyr Thr

1 5

<210> 2

<211> 12

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 2

Arg Val Glu Trp Met Gly Gly Glu Asp Pro Ile Leu

1 5 10

<210> 3

<211> 15

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 3

Gly Tyr Leu Ser Glu Thr Arg Arg Gln Gly Ser Glu Phe Leu Thr

1 5 10 15

<210> 4

<211> 120

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 4

Glu Val Arg Leu Val Glu Ser Gly Gly Gly Leu Val Gln Val Pro Asp

1 5 10 15

Asp Met Arg Leu Ser Cys Ala Ala Gln Gly Gly Gln Cys Asn Met Tyr

20 25 30

Val Pro Pro Ser Tyr Thr Trp Phe Arg Gln Ala Pro Gly Thr Trp Tyr

35 40 45

Asp Ser Val Ala Arg Val Glu Trp Met Gly Gly Glu Asp Pro Ile Leu

50 55 60

Arg Phe Thr Ile Ser Arg Thr Tyr Asp Asn Ala Lys Leu Thr Val Ser

65 70 75 80

Val Thr Pro Met His Glu Asp Thr Ala Val Asp Ile Leu His Phe Gly

85 90 95

Tyr Leu Ser Glu Thr Arg Arg Gln Gly Ser Glu Phe Leu Thr Trp Gly

100 105 110

Tyr Thr Gln Val Thr Val Ser Ser

115 120

Claims

1. A single domain antibody targeting IL-17, characterized in that the complementarity determining regions (CDR regions) of said single domain antibody have the amino acid sequences: CDR1 shown in SEQ ID NO. 1, CDR2 shown in SEQ ID NO. 2 and CDR3 shown in SEQ ID NO. 3.

2. The single domain antibody of claim 1, wherein the amino acid sequence of said single domain antibody is set forth in SEQ ID NO. 4.

3. A pharmaceutical composition comprising a single domain antibody as claimed in claim 1 or 2 and mesenchymal stem cell exosomes.

4. The pharmaceutical composition of claim 3, wherein the mass ratio of the single domain antibody to the mesenchymal stem cell exosomes is 1:2-2: 1.

5. The pharmaceutical composition of claim 3, wherein the preparation method of the mesenchymal stem cell exosome comprises: separating mesenchymal stem cells from umbilical cord tissues, carrying out subculture, culturing for 3-5 generations, replacing a serum-free culture medium for culturing for 24h when the fusion degree reaches more than 80%, collecting supernate, centrifuging, filtering and collecting.

6. The pharmaceutical composition of claim 3, wherein the mesenchymal stem cell exosomes are exosomes obtained after co-culturing mesenchymal stem cells with alveolar epithelial cells.

7. The pharmaceutical composition of claim 3, wherein the preparation method of the mesenchymal stem cell exosome comprises: separating mesenchymal stem cells from umbilical cord tissues, carrying out subculture, and culturing for 3-5 generations; inoculating the mesenchymal stem cells into a lower chamber of a Transwell culture chamber, and inoculating alveolar epithelial cells into an upper chamber of the Transwell culture chamber for co-culture; after co-culturing for a period of time, replacing serum-free culture medium to culture for 24h, collecting supernatant, centrifuging, filtering and collecting.

8. Use of a pharmaceutical composition according to claims 3-7 for the manufacture of a medicament for the treatment of a condition associated with tissue fibrosis.

9. Use according to claim 8, wherein the disease comprises pulmonary fibrosis, hepatic fibrosis, renal fibrosis or dermal fibrosis.

10. The use according to claim 9, wherein the disease is pulmonary fibrosis.